â– LECTURE OVERVIEW: Von Gierke Disease (Glycogen Storage Disease Type I) is a severe, hereditary metabolic disorder characterized by the liver's inability to release free glucose into the systemic circulation.
â– ENZYMATIC DEFICITS & CASCADING METABOLISMS:
1. The Primary Blocks:
- Type Ia (80%): Autosomal recessive deficiency of hepatic Glucose-6-Phosphatase (G6Pase), situated inside the endoplasmic reticulum lumen, which hydrolyzes G6P to free glucose.
- Type Ib: Deficient G6P Translocase, which transports G6P across the ER membrane.
2. Complete Pathway Blockage: Both glycogenolysis (glycogen breakdown) and gluconeogenesis (de novo glucose synthesis) converge on the conversion of G6P to free glucose. Thus, both pathways are completely blocked, causing profound, life-threatening fasting hypoglycemia.
3. Lactic Acidosis: Trapped G6P accumulates and is shunted down glycolysis, generating enormous amounts of pyruvate and lactate, resulting in metabolic lactic acidosis.
4. Hyperlipidemia & Facies: Glucagon and epinephrine stimulate adipose tissue lipolysis. The liver takes up these free fatty acids and converts them to VLDL and triglycerides, resulting in hepatosteatotic hepatomegaly and characteristic 'doll-like' facies from subcutaneous fat deposition.
5. Purine Overdrive & Gout: Accumulated G6P enters the HMP shunt, generating excess ribose-5-phosphate, driving de novo purine synthesis that degrades to uric acid, precipitating severe gout.
â– SURGICAL LANDMARKS & ANATOMICAL BOUNDARIES:
Intraoperative access requires meticulous dissection along defined tissue planes. Avoid excessive traction near neurovascular bundles and look for key bony landmarks or fascial reflections to secure margins.
â– GENOMIC VARIANT CHARACTERISTICS:
Molecular profiling indicates that specific genetic subtypes exhibit varying levels of enzyme activity and drug-clearance efficiency.
[HY-BOARD-1113]
🌟 Dynamic Clinical Key:
Managing GSD Type I requires the strict prevention of hypoglycemia. This is achieved by administering uncooked cornstarch (a complex polymer that releases glucose slowly at a steady rate over hours) and avoiding dietary galactose and fructose, which cannot be metabolized past G6P and would worsen lactic acidosis. Never divide or ligate any vessel before clearly isolating and confirming its origin and termination. Genetic screening profiles can help tailor precise therapeutic doses for optimal patient outcomes.